Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.12…

Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.12…

Big problem of IO access in control arm as trial was performed in countries lacking access. 40% of patients in control arm who got systemic therapy at relapse didn’t get IO. Censoring also an issue. The “positive” OS isn’t real. More info here…..ascopubs.org/doi/full/10.12…

Our new paper on class effects in oncology. A great opportunity for savings for health care payers, without impacting outcomes.

If you are an oncologist/trainee interested in the Common Sense Oncology movement you can contribute here Common Sense Oncology #commonsenseoncology:

🎧 Catch the latest episode of the Uromigos (Brian Rini, MD, Tom Powles) with Daniel Goldstein MD on dosing issues and dosing changes in drugs such as #nivolumab and #pembrolizumab, as well as other immune checkpoint inhibitors. 👂 Listen Here: buff.ly/3W7fDcG

Join us by Zoom for the first open plenary session of Common Sense Oncology . Register here- zoom.us/webinar/regist…

Totally love this. I’m proud to be an “old-fashioned” doctor!

US Senator now getting involved in cancer drug dosing issues

Thank you The Lancet Oncology for the shout out to Common Sense Oncology movement in the latest editorial. The editorial is excellent and open access. We highly encourage you to read it in its entirety. thelancet.com/journals/lanon…

Really great pleasure to help to run this workshop in Hong Kong. Thanks to Vivian Lee for amazing organization, and to Herbert Loong, MBBS, FASCO for being a great host to satisfy my foodie instincts!

ftm.eu/articles/cance…

Our new paper about overuse of PETCT using real world data from Clalit in Israel.

Vote for Chris - he definitely gets my full support!

With my friends Bishal Gyawali, MD, PhD, FASCO Daniel Goldstein MD #ESMO24

Our new paper - the tyranny of non-inferiority.